162 related articles for article (PubMed ID: 23246478)
1. Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies.
Helfand BT; Loeb S; Hu Q; Cooper PR; Roehl KA; McGuire BB; Baumann NA; Catalona WJ
J Urol; 2013 May; 189(5):1697-701. PubMed ID: 23246478
[TBL] [Abstract][Full Text] [Related]
2. Genetically adjusted prostate-specific antigen values may prevent delayed biopsies in African-American men.
Donin NM; Loeb S; Cooper PR; Roehl KA; Baumann NA; Catalona WJ; Helfand BT
BJU Int; 2014 Dec; 114(6b):E50-E55. PubMed ID: 24712975
[TBL] [Abstract][Full Text] [Related]
3. Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy.
Gilbert R; Martin RM; Evans DM; Tilling K; Davey Smith G; Kemp JP; Lane JA; Hamdy FC; Neal DE; Donovan JL; Metcalfe C
PLoS One; 2015; 10(10):e0136735. PubMed ID: 26431041
[TBL] [Abstract][Full Text] [Related]
4. Validation of association of genetic variants at 10q with prostate-specific antigen (PSA) levels in men at high risk for prostate cancer.
Chang BL; Hughes L; Chen DY; Gross L; Ruth K; Giri VN
BJU Int; 2014 May; 113(5b):E150-6. PubMed ID: 23937305
[TBL] [Abstract][Full Text] [Related]
5. Genetic correction of PSA values using sequence variants associated with PSA levels.
Gudmundsson J; Besenbacher S; Sulem P; Gudbjartsson DF; Olafsson I; Arinbjarnarson S; Agnarsson BA; Benediktsdottir KR; Isaksson HJ; Kostic JP; Gudjonsson SA; Stacey SN; Gylfason A; Sigurdsson A; Holm H; Bjornsdottir US; Eyjolfsson GI; Navarrete S; Fuertes F; Garcia-Prats MD; Polo E; Checherita IA; Jinga M; Badea P; Aben KK; Schalken JA; van Oort IM; Sweep FC; Helfand BT; Davis M; Donovan JL; Hamdy FC; Kristjansson K; Gulcher JR; Masson G; Kong A; Catalona WJ; Mayordomo JI; Geirsson G; Einarsson GV; Barkardottir RB; Jonsson E; Jinga V; Mates D; Kiemeney LA; Neal DE; Thorsteinsdottir U; Rafnar T; Stefansson K
Sci Transl Med; 2010 Dec; 2(62):62ra92. PubMed ID: 21160077
[TBL] [Abstract][Full Text] [Related]
6. Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with psa levels between 2.6 and 10.0 ng/mL.
Castro HAS; Iared W; Santos JEM; Solha RS; Shigueoka DC; Ajzen SA
Int Braz J Urol; 2018; 44(4):709-716. PubMed ID: 29697929
[TBL] [Abstract][Full Text] [Related]
7. Individualized prostate-specific antigen threshold values to avoid overdiagnosis of prostate cancer and reduce unnecessary biopsy in elderly men.
Kanao K; Komori O; Nakashima J; Ohigashi T; Kikuchi E; Miyajima A; Nakagawa K; Eguchi S; Oya M
Jpn J Clin Oncol; 2014 Sep; 44(9):852-9. PubMed ID: 25030213
[TBL] [Abstract][Full Text] [Related]
8. Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators.
Falagario UG; Martini A; Wajswol E; Treacy PJ; Ratnani P; Jambor I; Anastos H; Lewis S; Haines K; Cormio L; Carrieri G; Rastinehad AR; Wiklund P; Tewari A
Eur Urol Oncol; 2020 Oct; 3(5):700-704. PubMed ID: 31548130
[TBL] [Abstract][Full Text] [Related]
9. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
10. Clinical usefulness of free PSA in early detection of prostate cancer.
Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H;
Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
[TBL] [Abstract][Full Text] [Related]
11. Performance of Prostate Health Index in Biopsy Naïve Black Men.
Babajide R; Carbunaru S; Nettey OS; Watson KS; Holloway-Beth A; McDowell T; Ben Levi J; Murray M; Stinson J; Hollowell CMP; Dalton DP; Moore L; Kittles RA; Gann PH; Schaeffer EM; Murphy AB
J Urol; 2021 Mar; 205(3):718-724. PubMed ID: 33103942
[TBL] [Abstract][Full Text] [Related]
12. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
13. Are prostatic biopsies necessary in men aged > or =80 years?
Bott SR; Foley CL; Bull MD; Reddy CC; Freeman A; Montgomery BS; Langley SE
BJU Int; 2007 Feb; 99(2):335-8. PubMed ID: 17326264
[TBL] [Abstract][Full Text] [Related]
14. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
[TBL] [Abstract][Full Text] [Related]
15. Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index.
Aminsharifi A; Howard L; Wu Y; De Hoedt A; Bailey C; Freedland SJ; Polascik TJ
J Urol; 2018 Oct; 200(4):758-766. PubMed ID: 29758219
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer risk alleles are associated with prostate cancer volume and prostate size.
Reinhardt D; Helfand BT; Cooper PR; Roehl KA; Catalona WJ; Loeb S
J Urol; 2014 Jun; 191(6):1733-6. PubMed ID: 24345439
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG
Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426
[TBL] [Abstract][Full Text] [Related]
18. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA.
Parsons JK; Brawer MK; Cheli CD; Partin AW; Djavan R
BJU Int; 2004 Jul; 94(1):47-50. PubMed ID: 15217429
[TBL] [Abstract][Full Text] [Related]
19. Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies.
Steuber T; Tennstedt P; Macagno A; Athanasiou A; Wittig A; Huber R; Golding B; Schiess R; Gillessen S
BJU Int; 2019 May; 123(5):826-833. PubMed ID: 30216634
[TBL] [Abstract][Full Text] [Related]
20. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL.
Babaian RJ; Fritsche H; Ayala A; Bhadkamkar V; Johnston DA; Naccarato W; Zhang Z
Urology; 2000 Dec; 56(6):1000-6. PubMed ID: 11113747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
